{
  "abstract": "Targeting B-cell maturation antigen with chimeric antigen receptor (CAR) T-cells is a new standard of care in relapsed/refractory multiple myeloma (RRMM). However, long-term data have currently remained sparse. In a recent study published in the Journal for ImmunoTherapy of Cancer by Jin et al, authors reported on a large cohort of 141 patients with a median follow-up of 20.2 months. They found an overall response rate of 90.1% with 48.2% achieving a complete response. The median progression-free survival was 15.2 months, and the 4-year overall survival rate was 63.2%. In the current article, we summarize the published long-term data from clinically approved and investigational CAR T-cells for RRMM.",
  "authors": [
    {
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center, New York, New York, USA"
      ],
      "name": "Eric M Jurgens"
    },
    {
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center, New York, New York, USA"
      ],
      "name": "Saad Z Usmani"
    },
    {
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center, New York, New York, USA",
        "Leipzig University, Leipzig, Saxony, Germany"
      ],
      "name": "Maximilian Merz"
    }
  ],
  "title": "Mileage matters: long-distance performance of CARs in multiple myeloma",
  "uid": "f0424c40-b20b-5c3f-a383-8d4682cb70ec"
}